Results 51 to 60 of about 147,441 (251)

Recession Proof Pills: An Examination of the Relationship Between Recession Economics and Pharmaceutical Expenditures [PDF]

, 2012
The first decade of the 21st century proved to be a time of turbulence and volatility in the worldwide economy. Oddly enough, even as Americans’ disposable income decreased, spending on health care steadily increased.
Gray, Kevin
core   +2 more sources

Leveraging corona virus disease 2019 vaccination to promote hepatitis C screening

Hepatology Communications, EarlyView., 2022
Abstract Health care initiatives, such as hepatitis C virus (HCV) screening, have been greatly overshadowed by the corona virus disease 2019 (COVID‐19) pandemic. However, COVID‐19 vaccination programs also provide an opportunity to engage with a high volume of people in a health care setting.
Aaron Vanderhoff, David Smookler, Mia J. Biondi, Scott Enman, Tintin Fuliang, Sana Mahmood, Agustina Crespi, Maria Marquez, Rafique Van Uum, Lucy You, Brett Wolfson‐Stofko, Renee Logan, Erin LeDrew, Hemant Shah, Harry Janssen, Camelia Capraru, Elisa Venier, Jordan J. Feld   +17 more
wiley   +1 more source

Satisfaction with supplemental health insurance and pharmaceutical care among veterans and their families

Payesh, 2016
Objective (s): This study aimed to assess veterans and their families’ satisfaction with received supplementary pharmacy services, pharmacy location (distance) and the process of receiving costs. Methods: This was a cross-sectional study.
Batool Mousavi, Farzaneh Maftoon, Kazem Mohammad, Mohammadreza Soroush, Marziye Asgari   +4 more
doaj  

Directions of Changes in Health Care

Problemy Zarządzania, 2017
European societies, including Poland, are aging, and this increases the demand for health spending. The prices of new medicines and medical technologies will also increase.
Henryk Mruk
doaj   +1 more source

Health Care Opinion Leaders' Views on Slowing the Growth of Health Care Costs [PDF]

, 2009
Presents results of a survey of experts on the need to slow U.S. healthcare spending growth and on support for cost-reduction strategies, including payment reform and creating a center for comparative effectiveness, as proposed by the Obama ...
Karen Davis, Kristof Stremikis, Stuart Guterman   +2 more
core  

Issues for countries considering introducing the "fourth hurdle": The case of Hungary [PDF]

, 2004
Objectives: This study outlines the needs and current development of the "fourth hurdle" (i.e., requirement of effectiveness and cost-effectiveness data for drug coverage policy decisions) in Hungary, describes the legal background and seeks to address ...
Boncz, I, Drummond, M, Gulacsi, L
core   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

A new entity for the negotiation of public procurement prices for patented medicines in Mexico

Bulletin of the World Health Organization, 2012
PROBLEM: As countries expand health insurance coverage, their expenditures on medicines increase. To address this problem, WHO has recommended that every country draw up a list of essential medicines.
Octavio Gómez-Dantés, Veronika J Wirtz, Michael R Reich, Paulina Terrazas, Maki Ortiz   +4 more
doaj   +1 more source

Health Care Costs and the Arc of Innovation [PDF]

, 2019
Health care costs continue their inexorable rise, threatening America’s long-term fiscal stability, competitiveness, and standard of living. Over the past half-century, efforts to rein in spending have uniformly failed.
Bloche, Maxwell Gregg, Sukhatme, Neel U.
core   +2 more sources

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source